Ascendis submits FDA application to start cancer trial

A year and a half after announcing its strategy for entering the cancer area, Ascendis Pharma is now preparing to start clinical trials with its first drug candidate.

Photo: Kevin Grønnemann / MedWatch

Just before the new year, the biotech company Ascendis Pharma applied to the US Food and Drug Administration for permission to start running trials with a drug candidate for the treatment of cancer, according a company announcement.

On previous occasions, the firm presented three possible cancer candidates, and the first to be put through a clinical trial program is Transcon TLR7/8 Agonist, which is designed to enhance the immune system by imitating the proteins TLR7 and TLR8.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs